Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies

A. Verma, V. Essebag, P. Neuzil, K. Dyrda, J. Balt, B. Dinov, A. Darma, A. Arya, F. Sacher, VY. Reddy, L. Boersma, I. Grigorov, T. De Potter

. 2024 ; 26 (4) : . [pub] 20240330

Language English Country England, Great Britain

Document type Clinical Trial, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24014524

Grant support
Adagio Medical Inc

AIMS: The ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). METHODS AND RESULTS: This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1-9) to 0, IQR (0-2). CONCLUSION: In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. CLINICAL TRIAL REGISTRATION: NCT04893317.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014524
003      
CZ-PrNML
005      
20240905134048.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euae076 $2 doi
035    __
$a (PubMed)38582974
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Verma, Atul $u Division of Cardiology, McGill University Health Centre, D13.173, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada $1 https://orcid.org/0000000210209727
245    10
$a Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies / $c A. Verma, V. Essebag, P. Neuzil, K. Dyrda, J. Balt, B. Dinov, A. Darma, A. Arya, F. Sacher, VY. Reddy, L. Boersma, I. Grigorov, T. De Potter
520    9_
$a AIMS: The ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). METHODS AND RESULTS: This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1-9) to 0, IQR (0-2). CONCLUSION: In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. CLINICAL TRIAL REGISTRATION: NCT04893317.
650    _2
$a senioři $7 D000368
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a kardiomyopatie $x komplikace $x diagnóza $x chirurgie $7 D009202
650    12
$a katetrizační ablace $x škodlivé účinky $7 D017115
650    _2
$a jizva $x komplikace $7 D002921
650    12
$a kryochirurgie $x škodlivé účinky $7 D003452
650    _2
$a prospektivní studie $7 D011446
650    12
$a komorová tachykardie $x diagnóza $x etiologie $x chirurgie $7 D017180
650    _2
$a teplota $7 D013696
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Essebag, Vidal $u Division of Cardiology, McGill University Health Centre, D13.173, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada $1 https://orcid.org/0000000301075197
700    1_
$a Neuzil, Petr $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic $1 https://orcid.org/0000000343348165
700    1_
$a Dyrda, Katia $u Department of Medicine, Montreal Heart Institute, Montreal, QC, Canada $1 https://orcid.org/0000000201719311
700    1_
$a Balt, Jippe $u Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands $1 https://orcid.org/0000000278803730
700    1_
$a Dinov, Borislav $u Department of Electrophysiology, Leipzig Heart Center, Leipzig, Germany $1 https://orcid.org/0000000311048491
700    1_
$a Darma, Angeliki $u Department of Electrophysiology, Leipzig Heart Center, Leipzig, Germany $1 https://orcid.org/0000000347562775
700    1_
$a Arya, Arash $u Department for Internal Medicine, University Hospital Halle, Halle, Germany $1 https://orcid.org/0009000576109314
700    1_
$a Sacher, Frederic $u Bordeaux University Hospital, IHU LIRYC, University of Bordeaux, Bordeaux, France $1 https://orcid.org/0000000183489320
700    1_
$a Reddy, Vivek Y $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic $u Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, NY, USA $1 https://orcid.org/0000000256384993
700    1_
$a Boersma, Lucas $u Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands $u Department of Heart Failure and Arrhythmias,Amsterdam University Medical Center, Amsterdam, The Netherlands $1 https://orcid.org/0000000345914220
700    1_
$a Grigorov, Ilya $u Adagio Medical, Inc., Laguna Hills, CA, USA
700    1_
$a De Potter, Tom $u Cardiovascular Center, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium $1 https://orcid.org/000000031424114X
773    0_
$w MED00149837 $t Europace $x 1532-2092 $g Roč. 26, č. 4 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38582974 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134042 $b ABA008
999    __
$a ok $b bmc $g 2143968 $s 1226390
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 4 $e 20240330 $i 1532-2092 $m Europace $n Europace $x MED00149837
GRA    __
$p Adagio Medical Inc
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options